Sunday, April 09, 2023 8:03:10 PM
Here is a “hard working” Committee:
EANO ANNUAL REPORT 2021
PUBLICATION ACTIVITY COMMITTEE
The Publishing Activity Committee (Wolfgang Wick, DE (Chair), Martin Taphoorn, NL (co-chair), Linda Dirven, NL, Francois Ducray, FR, Norbert Galldiks, DE, Monika Hegi, CH, Martin Klein, DE, Katrin Lamszus, DE, Simone Niclou, LU, Matthias Preusser, AT, Patrick Roth, CH, Roberta Rudà, IT, Felix Sahm, DE, Susan Short, UK, Riccardo Soffietti, IT, Martin Van den Bent, NL, Michael Weller, CH, Pieter Wesseling, NL) consists of editors that represent EANO in the following journals: Neuro-Oncology, Neuro-Oncology Practice and Neuro-Oncology Advances. The main tasks of the committee are to ensure scientific representation of EANO in the journals, providing a link between EANO and the journal publisher and promoting the publication activities within the EANO membership.
https://www.eano.eu/fileadmin/user_upload/0078_EANO_Annual_Report_2021.pdf
Wolfgang Wick : First results on the DCVax phase III trial: raising more questions than providing answers . https://pubmed.ncbi.nlm.nih.gov/30137551/
Matthias Preusser : Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana? https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false
Susan Short : one of the co-signees of the JAMA “Comment”.
Comment
November 30, 2022
The need to report as-planned analyses and the weakness of historical controls
Dr. Matt Williams, London
Dr. Paul Sanghera, Birmingham
Prof. Susan Short, Leeds
Dr. Anup Vinayan, London
Dr. Juliet Brock, Oxford
Dr. Chris Herbert, Bristol
Dr. Joanne Lewis, Newcastle
Dr. Shaveta Mehta, Liverpool
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
Patrick Roth : Vaccination ( negative phase 3 trials: ACT-IV, DCVax-L) https://investorshub.advfn.com/boards/read_msg.aspx?message_id=167233202
Martin J van den Bent :
First results on the DCVax phase III trial: raising more questions than providing answers.https://pubmed.ncbi.nlm.nih.gov/30137551/
Autologous tumor lysate-loaded dendritic cell vaccination (DCVax-L) in glioblastoma: Breakthrough or fata morgana? https://academic.oup.com/neuro-oncology/article/25/4/631/6958519?login=false
Michael Weller - 2016 - Min 10.30
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
